OpenEvidence
Category: AI in Healthcare
A specialized AI-powered clinical decision support platform that provides physicians with real-time, evidence-based, and peer-reviewed answers to complex medical questions. OpenEvidence was founded in 2021. The company is led by Daniel Nadler. Based in Miami, USA. Team size: 11-50. Total funding raised: ~$700M total. Latest round: Series D ($250M, Jan 2026 at $12B valuation). Key investors include Thrive Capital, DST Global, Sequoia Capital, GV (Google Ventures), Kleiner Perkins, Nvidia, Coatue, ICONIQ, Mayo Clinic, Spark Capital.
AMW Analysis
OpenEvidence operates a clinical decision support platform built specifically for physicians, using peer-reviewed literature to answer complex medical questions and reduce reliance on manual research at the point of care. Founded in 2021 and based in Miami, the company has raised roughly $700 million to date from investors including Thrive Capital, Sequoia Capital, GV, Kleiner Perkins, Nvidia, and Mayo Clinic, among others.
News flow shows rapid, closely spaced valuation increases: a Series D of $250 million in January 2026 valued the company at $12 billion, up from a reported $6 billion the prior October, and by July 2026 it had received an unsolicited $200 million offer implying a roughly $20 billion valuation, which it declined. Reporting describes adoption among a large share of U.S. physicians, tens of millions of monthly consultations, and revenue tied to a subscription and advertising model aimed at pharmaceutical companies. Coverage frames the company as evidence of vertical, domain-specific AI scaling quickly within healthcare, with growth reported as outpacing typical timelines for reaching comparable revenue levels.
AMW analysis, generated from 5 tracked news signals.
- Founded
- 2021
- Headquarters
- Miami, USA
- Team size
- 11-50
- Total funding
- ~$700M total
Value proposition
Eliminates medical information overload by synthesizing vast amounts of peer-reviewed literature into actionable clinical insights, reducing physician burnout and improving diagnostic accuracy.
Products and solutions
OpenEvidence Clinical Search Engine, USMLE-Validated Medical LLM, Evidence-Based Citation System (Primary Source Linking), Institutional Clinical Decision Support API
Unique value
It is the first AI system to pass the United States Medical Licensing Examination (USMLE) and is specifically engineered to prioritize peer-reviewed medical literature over general web data to prevent hallucinations.
Target customer
Physicians, clinicians, medical researchers, healthcare systems, and medical students.
Industries served
Healthcare, Medical Education, Biotechnology, Pharmaceuticals
Technology advantage
Utilizes proprietary 'grounded' AI models that link every response to high-quality medical evidence; benefits from a strategic validation partnership with the Mayo Clinic and the leadership of Daniel Nadler, who previously scaled Kensho Technologies.
How they differentiate
OpenEvidence differentiates through its 'grounded' AI architecture that eliminates hallucinations by citing every sentence to peer-reviewed medical literature. Unlike legacy tools like UpToDate which rely on human-authored summaries, OpenEvidence provides real-time synthesis of the entire PubMed database and was the first AI to pass the USMLE.
Main competitors
UpToDate (Wolters Kluwer), Glass Health, Consensus, Perplexity (Medical)
Key partnerships
Mayo Clinic (Strategic partner for clinical validation and development), Harvard University (Academic and research collaboration), Major U.S. Healthcare Systems
Notable customers
Mayo Clinic, Harvard Medical School, Major U.S. Health Systems
Major milestones
First AI system to pass the United States Medical Licensing Examination (USMLE), Established strategic validation partnership with Mayo Clinic Platform, Founder Daniel Nadler named to TIME100 Health 2024, Reached $12B valuation with $250M Series D in January 2026
Growth metrics
Used by clinicians across more than 2,000 healthcare institutions; valuation reached $12B as of January 2026.
Market positioning
Premium AI-native clinical decision support (CDS) platform for healthcare professionals and institutional health systems.
Geographic focus
Global (Primary focus on North America and European medical markets)
Patents and IP
Proprietary medical-grade LLM architectures and citation-verification algorithms (Specific public patent filings not disclosed).
About Daniel Nadler
Dr. Daniel Nadler is a serial entrepreneur and the founder of OpenEvidence. He previously founded Kensho Technologies, a leading provider of AI and machine learning to the financial industry, which was acquired by S&P Global in 2018 for approximately $550 million—at the time, the largest AI acquisition in history. He holds a PhD from Harvard University and has been recognized as a global leader in applying specialized AI to high-stakes industries.
Latest news about OpenEvidence
- OpenEvidence nears $30B valuation as healthcare AI platform proves vertical specialization can outrun general-purpose models
- OpenEvidence reached a 12 billion valuation following a 250 million Series D, hitting a 100 million revenue run rate in under 12 months. With 430,000 clinicians generating 20 million monthly conversat
- OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by Thrive Capital. Used by 50 percent of U.S. physicians and processing 18 million monthly consultations
- OpenEvidence has secured 250 million dollars at a 12 billion dollar valuation, cementing its role as the primary AI infrastructure for U.S. healthcare. With 40 percent of domestic physicians already u
- OpenEvidence, the "ChatGPT for doctors," recently secured $250M, elevating its valuation to $12B. This remarkable leap from $6B in October is fueled by over $100M in annual revenue from healthcare sub
More AI in Healthcare companies
Official website: https://www.openevidence.com
